The P-III (ECHO) study investigates the safety & efficacy of Calquence + bendamustine and rituximab vs SoC CT (bendamustine and rituximab) in treatment-naïve MCL patients (n=598, over 65yrs.) in North and South America, EU, Asia and Oceania
The interim analysis depicted an improved PFS with Calquence combination regimen vs SoC along with an OS trend favoring the regimen though the OS data was immature during analysis and the study is underway for its evaluation
Additionally, Calquence is also being assessed as monotx. and in combinations to treat several B-cell blood cancers such as CLL, MCL, and diffuse large B-cell lymphoma
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca’s Calquence (acalabrutinib) Receives NMPA’s Approval for Chronic Lymphocytic Leukaemia in China
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
